Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Celldex Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analysts, with a 12-month average price target of $44.20.
• The company's shares recently opened at $26.26, marking a 12-month low of $14.40 and a high of $29.38.
• In the latest earnings report, Celldex posted an EPS of ($0.85), slightly better than the consensus estimate of ($0.86), but with revenue falling short at $0.73 million.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $44.20.

A number of research firms have recently issued reports on CLDX. Weiss Ratings reissued a "sell (d-)" rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group restated a "buy" rating and set a $62.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. HC Wainwright dropped their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating for the company in a research note on Wednesday, August 20th. Mizuho started coverage on Celldex Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $48.00 target price on the stock. Finally, Wells Fargo & Company lowered their target price on Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a report on Wednesday, August 20th.

Celldex Therapeutics Trading Down 1.7%

Shares of NASDAQ:CLDX opened at $26.26 on Friday. Celldex Therapeutics has a 12-month low of $14.40 and a 12-month high of $29.38. The business has a 50 day moving average of $24.85 and a two-hundred day moving average of $22.04. The company has a market capitalization of $1.74 billion, a PE ratio of -8.72 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. Equities research analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in CLDX. Handelsbanken Fonder AB boosted its position in Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 500 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 501 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock valued at $798,000 after purchasing an additional 680 shares during the period. AlphaQuest LLC grew its stake in Celldex Therapeutics by 7.0% during the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company's stock worth $264,000 after purchasing an additional 844 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 881 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.